Profluent
AI-First Protein Design
Berkeley, California, USA
Profluent is an AI-first protein design company that leverages its platform for CRISPR gene editing systems to accelerate the development of genetic medicines.
How We Help
Problem Statement
Profluent aims to solve challenges in human health and the environment by developing innovative, functional proteins, particularly for genetic disorders like Rett Syndrome, through AI-driven base editing.
Core Technology
AI-driven biological programming
Key Differentiators
AI-first approach to protein design; Integration of large-scale frontier AI models and wet-lab capabilities; World's first open-source, AI-generated gene editor (OpenCRISPR-1); Focus on making biology programmable
Clinical Focus
Development of novel therapeutics through AI-driven protein design, with an initial emphasis on gene editing, particularly CRISPR systems, and expanding into antibodies, antigens, and enzymes for targeted disease treatments like Rett syndrome.
Target Customers
Innovative companies and partners across various therapeutic verticals.
Product Stage
Beta
Company Info
- Business Model
- B2B
- Founded
- 2022
- Total Funding
- 106,000,000
- Website
- profluent.com/
Categories
Technologies
MedStartr Index Score
?What do you think of Profluent?
A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.